Kisspeptin Phase 1 Trial NCT07224490 Now Recruiting

On July 13, 2026, a Phase 1 clinical trial involving kisspeptin was listed as recruiting on ClinicalTrials.gov. The trial, registered as NCT07224490, is titled "Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease." Kisspeptin remains classified as an unapproved compound used in research settings. According to the registry entry, the study is currently in Phase 1 and actively recruiting participants as of the listed date. The trial's stated purpose, per its title, is to quantify GnRH neuronal function in both healthy individuals and those with disease. No results, efficacy data, or safety findings have been posted for this trial as of this update. The current status reflects only that recruitment is underway, not any outcomes or conclusions. Readers should note that Phase 1 trials are early-stage studies and their designation as recruiting does not indicate any therapeutic benefit or established use. Further updates on this trial's progress may become available as it advances through subsequent phases or as recruitment concludes. For more background on kisspeptin, including its regulatory status and general context, see the compound overview.